JPRN-UMIN000016525招募中1 期
Phase 1 study to examine the safety and dose-dependent effect of rapamycin topical medicine on perspiration in healthy volunteers - Phase 1 study to examine the safety and dose-dependent effect of rapamycin topical medicine on perspiration in healthy volunteers
Department of Dermatology Graduate School of Medicine, Osaka University0 个研究点目标入组 12 人开始时间: 2015年2月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) A person who cannot carry out this treatment plan. 2) A person who have allergy to macrolide antibiotics. 3) A person who received oral administration of rapamycin or RAD001 within 12 months prior to the study entry. 4) A person who received topical administration of rapamycin or RAD001 within three days prior to the study entry. 5) A person who received topical treatment of aluminum chloride or iontophoresis within one months prior to the study entry. 6) A person who received local injection of Botox within three months prior to the study entry. 7) A person who received sympathectomy within 12 months prior to the study entry. 8) A person during pregnancy or lactation 9) A person who cannot undergo QSART and starch-iodine test 10) A person who were judged unsuitable for this study by the investigator.
研究者
相似试验
已完成
不适用
Phase I clinical study to evaluate the safety and tolerability of Quadrivalent Influenza Vaccine (QIV) delivered intradermally by a high-density micro-array patch (HD MAP), compared to intramuscular Influvac® Tetra injection, in healthy adults aged 18 to 50 yearsrespiratory infectionRespiratory - Other respiratory disorders / diseasesInfluenzaACTRN12622001203741Vaxxas Pty Ltd150
已完成
不适用
Phase I clinical study to evaluate the safety and tolerability of SARS-CoV-2 spike protein (HexaPro) delivered intradermally by a high-density microarray patch (HD-MAP), in healthy adults aged 18 to 50 years.SARS-CoV-2 infectionInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12622000597796Vaxxas Pty Ltd44
进行中（未招募）
1 期
A Phase I clinical trial to assess the safety and immunogenicity of HIV DNA immunisations administered via the Intramuscular and Intradermal methods with and without electroporation followed by boosting with recombinant HIV protein in healthy male and female volunteersHIV prophylaxisMedDRA version: 18.0 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestationsEUCTR2015-001023-23-GBImperial College London28
招募中
不适用
A phase 1 clinical trial to evaluate the safety and pharmacokinetic characteristics after administration of fixed-dose combination of NGL-101 and loose-combination of each component in healthy adult volunteersKCT0007258Chungbuk National University Hospital40
已完成
不适用
Comparison of pharmacokinetics between administration of fixed-dose combination or loose combination of HUG186(Bazedoxifene and Cholecalciferol)KCT0003839Huons52